Roderick Kim, MD
Internal Medicine · Grand Rapids, MINPI 1922066984
Payments from drug & device makers
Across 106 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$246
- Boehringer Ingelheim$188
- Novartis$145
- Merck$142
- Daiichi Sankyo Inc.$137
- E.r. Squibb & Sons, L.L.C.$115
- plus $1K from 25 others
What the payments were for
- Food & beverage$1,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $246 |
| Boehringer Ingelheim | 9 | $188 |
| Novartis | 7 | $145 |
| Merck | 6 | $142 |
| Daiichi Sankyo Inc. | 7 | $137 |
| E.r. Squibb & Sons, L.L.C. | 7 | $115 |
| Lilly USA, LLC | 6 | $110 |
| Bayer | 5 | $83 |
| GSK | 4 | $75 |
| AbbVie | 3 | $72 |
| Amgen | 4 | $58 |
| Johnson & Johnson | 4 | $55 |
| AstraZeneca(2 entities) | 3 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Sanofi Pasteur Inc. | 3 | $53 |
| Pfizer | 3 | $52 |
| Exact Sciences | 2 | $39 |
| Dexcom, Inc. | 2 | $32 |
| Abbott | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $23 |
| GRT US Holding, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $14 |
| Gilead | 1 | $14 |
How this compares
$1,985 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $67,756 |
| TrulicityDulaglutide | 55 | $63,986 |
| XareltoRivaroxaban | 34 | $41,404 |
| OzempicSemaglutide | 35 | $40,522 |
| MounjaroTirzepatide | 32 | $35,298 |
| JanuviaSitagliptin Phosphate | 24 | $31,309 |
| JardianceEmpagliflozin | 23 | $29,060 |
| Atorvastatin Calcium | 599 | $11,429 |
| Omeprazole | 343 | $7,405 |
| Levothyroxine Sodium | 339 | $6,713 |
| Arnuity ElliptaFluticasone Furoate | 12 | $6,453 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $5,762 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $5,499 |
| Alendronate Sodium | 161 | $5,209 |
| Metoprolol Succinate | 180 | $5,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $110 | $99,28487 claims |
| PfizerEliquis | $52 | $67,75653 claims |
| Johnson & JohnsonXarelto | $55 | $41,40434 claims |
| Novo NordiskOzempic | $246 | $40,52235 claims |
| MerckJanuvia | $142 | $31,30924 claims |
| Boehringer IngelheimJardiance | $188 | $29,06023 claims |
| GSKArnuity Ellipta, Shingrix | $75 | $10,53730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Grand Rapids
- Leslie PelkeyGrand Rapids$8.5M
- Khan NeddGrand Rapids$2.2M
- Robert SelfeGrand Rapids$238K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.